On Tuesday, H.C. Wainwright adjusted its price target for Tourmaline Bio (NASDAQ:TRML), increasing it to $49.00 from the previous $48.00, while reaffirming a Buy rating on the stock. The firm's decision came after Tourmaline Bio disclosed its third-quarter financial results for 2024 last week.
The company reported a net loss of $20.2 million, or ($0.78) per share, which was marginally above the estimated loss of $19.3 million projected by H.C. Wainwright.
Tourmaline Bio's management highlighted the progress of their ongoing Phase 2b spiriTED trial of pacibekitug, also known as TOUR006, for the treatment of thyroid eye disease (TED). Topline results from this trial are anticipated in the second half of 2025. Additionally, the company is gearing up to initiate a Phase 3 trial of pacibekitug in TED, which is the second pivotal trial, and is scheduled to begin in the latter half of 2024.
The firm noted that the inclusion of clinical sites outside the U.S. is expected to expedite enrollment for the trials. Looking ahead, the Phase 3 trial is projected to yield topline data by 2026. H.C. Wainwright expressed continued confidence in pacibekitug's potential as a first-line therapy for TED.
In their commentary, H.C. Wainwright estimated the current market value of Tourmaline Bio at approximately $1.26 billion, or $49 per share. This valuation underpins their decision to maintain a Buy rating and to revise the 12-month price target upwards by $1.00. The firm's positive outlook on Tourmaline Bio reflects their anticipation of the drug's future market impact and the company's ongoing clinical developments.
In other recent news, Tourmaline Bio has been the subject of several significant developments. The company's Chief Medical (TASE:PMCN) Officer, Dr. Yung Chyung, announced his resignation, effective October 31, 2024, to pursue a different opportunity.
The company has also formed a Cardiovascular Scientific Advisory Board to provide strategic guidance for pacibekitug as it progresses towards Phase 3 clinical trial readiness in 2025.
Furthermore, Tourmaline Bio will present two research posters at the 19th Annual Cardiometabolic Health Congress, highlighting the role of IL-6 inhibition in cardiovascular risk and the use of high-sensitivity C-Reactive Protein testing in preventing atherosclerotic cardiovascular disease.
Guggenheim maintained its Buy rating on Tourmaline Bio shares, despite the departure of the CMO. The firm's confidence is based on the company's focus on its cardiovascular program and the therapeutic potential of targeting IL-6 in cardiovascular disease management.
InvestingPro Insights
Tourmaline Bio's recent financial performance and future prospects, as highlighted in the article, can be further contextualized with real-time data from InvestingPro. The company's market capitalization stands at $726.2 million, which is notably lower than H.C. Wainwright's estimated market value of $1.26 billion. This discrepancy suggests potential upside if the company's clinical trials yield positive results.
InvestingPro data reveals that Tourmaline Bio has experienced strong returns over various time frames, with a 72.26% price total return over the past year and an impressive 101.57% return over the last three months. These figures align with the positive sentiment expressed in the article and the increased price target set by H.C. Wainwright.
However, it's important to note that Tourmaline Bio is currently not profitable, with a negative EBITDA of -$78.78 million for the last twelve months as of Q3 2024. This aligns with the company's reported net loss and reflects its status as a clinical-stage biopharmaceutical company investing heavily in research and development.
Two key InvestingPro Tips provide additional context:
1. Tourmaline Bio holds more cash than debt on its balance sheet, which is crucial for a company in the development stage of novel therapeutics.
2. The company's liquid assets exceed short-term obligations, indicating a solid financial position to fund ongoing clinical trials.
These insights suggest that while Tourmaline Bio is not yet profitable, it maintains a strong financial foundation to support its ongoing clinical programs, including the pivotal trials for pacibekitug mentioned in the article.
For investors seeking a more comprehensive analysis, InvestingPro offers 10 additional tips that could provide deeper insights into Tourmaline Bio's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.